BIOMEA FUSION INC Share Price Today: Live Updates & Key Insights

BIOMEA FUSION INC share price today is $1.25, up -0.79%. The stock opened at $1.24 against the previous close of $1.26, with an intraday high of $1.295 and low of $1.23.

BIOMEA FUSION INC Share Price Chart

BIOMEA FUSION INC

us-stock
To Invest in {{usstockname}}
us-stock

BIOMEA FUSION INC Share Price Performance

$1.25 -0.0079(-0.79%) BMEA at 27 Jul 2026 02:14 PM Biotechnology
Lowest Today 1.23
Highest Today 1.295
Today’s Open 1.24
Prev. Close 1.26
52 Week High 2.99
52 Week Low 0.87
Day’s Range: Low 1.23 High 1.295
52-Week Range: Low 0.87 High 2.99
1 day return -
1 Week return -3.81
1 month return -4.54
3 month return -27.79
6 month return -
1 year return -30.76
3 year return -93.47
5 year return -89.92
10 year return -

BIOMEA FUSION INC Institutional Holdings

FMR Inc 12.19

Fidelity Growth Compy Commingled Pl S 5.45

Vanguard Group Inc 4.11

Fidelity Growth Company Fund 3.75

Vanguard Capital Management, LLC 3.59

Vanguard Total Stock Mkt Idx Inv 2.94

Aisling Capital Management LP 2.83

Renaissance Technologies Corp 1.82

Marshall Wace Asset Management Ltd 1.66

Fidelity Growth Company K6 1.25

Fidelity Series Growth Company 1.11

Citadel Advisors Llc 0.91

Mariner Wealth Advisors LLC 0.91

BlackRock Inc 0.89

Vanguard Institutional Extnd Mkt Idx Tr 0.88

Susquehanna International Group, LLP 0.87

Fideuram - Intesa Sanpaolo Private Banking Spa 0.77

Geode Capital Management, LLC 0.76

XTX Topco Ltd 0.73

UBS Group AG 0.71

Fidelity Select Biotechnology 0.63

Two Sigma Investments LLC 0.54

Morgan Stanley - Brokerage Accounts 0.48

Vanguard Fiduciary Trust Co 0.46

Jacobs Levy Equity Management, Inc. 0.43

Fidelity Extended Market Index 0.40

Jane Street Group LLC 0.38

SUPERSTRING CAPITAL MANAGEMENT LP 0.35

iShares Micro-Cap ETF 0.32

Blackrock Extended Mkt Fund CF 0.21

Extended Equity Market Fund B 0.21

Extended Equity Market Fund E 0.21

BlackRock Extended Equity Market Fund K 0.18

Fidelity Total Market Index 0.15

Bridgeway Ultra-Small Company Market 0.12

Fidelity Series Total Market Index 0.11

Spartan Extended Market Index Pool F 0.11

Northern Trust Extended Eq Market Idx 0.09

NT Ext Equity Mkt Index Fund - Lending 0.09

NT Ext Equity Mkt Index Fund - NL 0.08

BIOMEA FUSION INC Market Status

Strong Buy: 4

Buy: 3

Hold: 2

Sell: 0

Strong Sell: 0

BIOMEA FUSION INC Fundamentals

Market Cap 93.27 M

PB Ratio 4.9824

PE Ratio 0.0

Enterprise Value 49.81 M

Total Assets 58.57 M

Volume 398411

BIOMEA FUSION INC Company Financials

Annual Revenue FY23:0 0.0M, FY22:0 0.0M, FY21:0 0.0M, FY20:0 0.0M, FY19:0 0.0M

Annual Profit FY23:null 0.0M, FY22:null 0.0M, FY21:null 0.0M, FY20:null 0.0M, FY19:null 0.0M

Annual Net worth FY23:-107685000 -107.7M, FY22:-80022000 -80.0M, FY21:-41218000 -41.2M, FY20:-5324000 -5.3M, FY19:-1198000 -1.2M

Quarterly Revenue Q1/2026:0 0.0M, Q3/2025:0 0.0M, Q2/2025:0 0.0M, Q1/2025:0 0.0M, Q3/2024:0 0.0M

Quarterly Profit Q1/2026:-46000 -0.0M, Q3/2025:-400000 -0.4M, Q2/2025:-500000 -0.5M, Q1/2025:null 0.0M, Q3/2024:-400000 -0.4M

Quarterly Net worth Q1/2026:-12415000 -12.4M, Q3/2025:-16407000 -16.4M, Q2/2025:-20740000 -20.7M, Q1/2025:-29262000 -29.3M, Q3/2024:-32787000 -32.8M

About BIOMEA FUSION INC & investment objective

Company Information Biomea Fusion, Inc., a clinical-stage diabetes and obesity medicines company, focuses on the discovery and development of oral drugs to treat patients with diabetes and obesity. It's lead clinical program's drug candidates are COVALENT-111 and COVALENT-112, which has completed Phase II clinical trials of icovamenib for the treatment of Type 1 and Type 2 diabetes; COVALENT-211, which is in Phase II clinical trial of icovamenib for treating insulin-deficient type 2 diabetes; and COVALENT-212, which is in Phase II clinical trial of icovamenib for the treatment of type 2 diabetes. The company is also developing BMF-650, which is in Phase I glucagon-like peptide-131 clinical trial for the treatment of obesity. The company was incorporated in 2017 and is headquartered in San Carlos, California.

Organisation Biotechnology

Employees 40

Industry Biotechnology

CEO Dr. Michael J. M. Hitchcock Ph.D.

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right

BIOMEA FUSION INC FAQs

What is the share price of BIOMEA FUSION INC today?

The current share price of BIOMEA FUSION INC is $1.25.

Can I buy BIOMEA FUSION INC shares in India?

Yes, Indian investors can buy BIOMEA FUSION INC shares by opening an international trading and demat account with Motilal Oswal.

How to buy BIOMEA FUSION INC shares in India?

You can easily invest in BIOMEA FUSION INC shares from India by:

Can I buy fractional shares of BIOMEA FUSION INC?

Yes, many platforms allow you to buy fractional shares starting from as low as $1.

What is the market capitalization value of BIOMEA FUSION INC?

BIOMEA FUSION INC has a market cap of $93.27 M.

In which sector does BIOMEA FUSION INC belong?

BIOMEA FUSION INC operates in the Biotechnology sector.

What documents are required to invest in BIOMEA FUSION INC stocks?

To invest, you typically need:

What is the PE and PB ratio of BIOMEA FUSION INC?

The PE ratio of BIOMEA FUSION INC is N/A and the PB ratio is 4.98.